Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: Evidence for a new erythropoietin/hemoglobin set point

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 69, Issue 6, 2014, Pages 725-735

  Bachman, Eric ^a   Travison, Thomas G ^b   Basaria, Shehzad ^a   Davda, Maithili N ^b   Guo, Wen ^b   Li, Michelle ^b   Connor Westfall, John ^a   Bae, Harold ^a   Gordeuk, Victor ^b   Bhasin, Shalender ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Erythropoietin; Ferritin; Hepcidin; Testosterone

Indexed keywords

ANDROGEN; ERYTHROPOIETIN; HEMOGLOBIN; HEPCIDIN; TESTOSTERONE;

AGED; ARTICLE; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; ERYTHROPOIESIS; FERRITIN.; FOLLOW UP; HUMAN; MALE; METABOLISM; MIDDLE AGED; POLYCYTHEMIA; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WALKING DIFFICULTY;

ERYTHROPOIETIN; FERRITIN.; HEPCIDIN; TESTOSTERONE;

AGED; ANDROGENS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ERYTHROPOIESIS; ERYTHROPOIETIN; FOLLOW-UP STUDIES; HEMOGLOBINS; HEPCIDINS; HUMANS; MALE; MIDDLE AGED; MOBILITY LIMITATION; POLYCYTHEMIA; RADIOIMMUNOASSAY; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84896285751     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/glt154     Document Type: Article

References (44)

1. Liverman CT, Blazer DG. Testosterone and Aging: Clinical ResearchDirections. Washington, DC: Joseph Henry Press; 2004.
2. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy inmen with androgen deficiency syndromes: an Endocrine Society clinicalpractice guideline. J Clin Endocrinol Metab. 2010;95:2536-2559.
3. Calof OM, Singh AB, Lee ML, et al. Adverse events associated withtestosterone replacement in middle-aged and older men: a meta-analysisof randomized, placebo-controlled trials. J Gerontol A Biol SciMed Sci. 2005;60:1451-1457.
4. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, BhasinS. Effects of graded doses of testosterone on erythropoiesis in healthyyoung and older men. J Clin Endocrinol Metab. 2008;93:914-919.
5. Mirand EA, Gordon AS, Wenig J. Mechanism of testosterone action inerythropoiesis. Nature 1965;206(981):270-272.
6. Shahani S, Braga-Basaria M, Maggio M, Basaria S. Androgensand erythropoiesis: past and present. J Endocrinol Invest.2009;32(8):704-716.
7. Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. AnnuRev Med. 2011;62:347-360.
8. Ip FF, di Pierro I, Brown R, Cunningham I, Handelsman DJ, Liu PY.Trough serum testosterone predicts the development of polycythemiain hypogonadal men treated for up to 21 years with subcutaneous testosteronepellets. Eur J Endocrinol. 2010;162(2):385-390.
9. Rochira V, Zirilli L, Madeo B, Maffei L, Carani C. Testosterone actionon erythropoiesis does not require its aromatization to estrogen:insights from the testosterone and estrogen treatment of two aromatasedeficientmen. J Steroid Biochem Mol Biol. 2009;113:189-194.
10. Maggio M, Snyder PJ, Ceda GP, et al. Is the haematopoietic effect oftestosterone mediated by erythropoietin? The results of a clinical trialin older men. Andrology. 2013;1(1):24-28.
11. Blanchard KL, Acquaviva AM, Galson DL, Bunn HF. Hypoxic inductionof the human erythropoietin gene: cooperation between the promoterand enhancer, each of which contains steroid receptor responseelements. Mol Cell Biol. 1992;12:5373-5385.
12. Bachman E, Feng R, Travison T, et al. Testosterone suppresses hepcidinin men: a potential mechanism for testosterone-induced erythrocytosis.J Clin Endocrinol Metab. 2010;95:4743-4747.
13. Basaria S, Coviello AD, Travison TG, et al. Adverse events associatedwith testosterone administration. N Engl J Med. 2010;363:109-122.
14. Mazer NA. A novel spreadsheet method for calculating the free serumconcentrations of testosterone, dihydrotestosterone, estradiol, estroneand cortisol: with illustrative examples from male and female populations.Steroids. 2009;74:512-519.
15. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassayfor human serum hepcidin. Blood. 2008;112:4292-4297.
16. Izaks GJ, Westendorp RG, Knook DL. The definition of anemia inolder persons. JAMA. 1999;281:1714-1717.
17. Jockenhovel F, Vogel E, Reinhardt W, Reinwein D. Effects of variousmodes of androgen substitution therapy on erythropoiesis. Eur J MedRes. 1997;2:293-298.
18. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosteronereplacement in hypogonadal men. J Clin Endocrinol Metab.2000;85:2670-2677.
19. Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosteroneon muscle strength, physical function, body composition,and quality of life in intermediate-frail and frail elderly men: a randomized,double-blind, placebo-controlled study. J Clin EndocrinolMetab. 2010;95:639-650.
20. Fernandez-Balsells MM, Murad MH, Lane M, et al. Clinicalreview 1: adverse effects of testosterone therapy in adult men: asystematic review and meta-analysis. J Clin Endocrinol Metab.2010;95:2560-2575.
21. Beguin Y, Clemons GK, Oris R, Fillet G. Circulating erythropoietinlevels after bone marrow transplantation: inappropriate response toanemia in allogeneic transplants. Blood. 1991;77:868-873.
22. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor andits ratio to serum ferritin in the diagnosis of iron deficiency. Blood.1997;89:1052-1057.
23. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia ofinflammation by inducing the synthesis of the iron regulatory hormonehepcidin. J Clin Invest. 2004;113:1271-1276.
24. Gordeuk VR, Sergueeva AI, Miasnikova GY, et al. Congenital disorderof oxygen sensing: association of the homozygous Chuvash polycythemiaVHL mutation with thrombosis and vascular abnormalitiesbut not tumors. Blood. 2004;103:3924-3932.
25. Huebers HA, Beguin Y, Pootrakul P, Einspahr D, Finch CA. Intacttransferrin receptors in human plasma and their relation to erythropoiesis.Blood. 1990;75:102-107.
26. Guo W, Bachman E, Li M, et al. Testosterone administration inhibitshepcidin transcription and is associated with increased iron incorporationinto red blood cells. Aging Cell 2013;12(2):280-291.
27. Pietrangelo A. Hemochromatosis: an endocrine liver disease.Hepatology. 2007;46(4):1291-1301.
28. Lesbordes-Brion JC, Viatte L, Bennoun M, et al. Targeted disruptionof the hepcidin 1 gene results in severe hemochromatosis. Blood.2006;108(4):1402-1405.
29. Mok H, Jelinek J, Pai S, et al. Disruption of ferroportin 1 regulationcauses dynamic alterations in iron homeostasis and erythropoiesis inpolycythaemia mice. Development. 2004;131(8):1859-1868.
30. Moriyama Y, Fisher JW. Effects of testosterone and erythropoietin onerythroid colony formation in human bone marrow cultures. Blood.1975;45:665- 670.
31. Malgor LA, Valsecia M, Verges E, De Markowsky EE. Blockade of thein vitro effects of testosterone and erythropoietin on Cfu-E and Bfu-Eproliferation by pretreatment of the donor rats with cyproterone andflutamide. Acta Physiol Pharmacol Ther Latinoam. 1998;48:99-105.
32. Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors.Blood Rev. 2013;27(1):41-53.
33. Pan X, Suzuki N, Hirano I, Yamazaki S, Minegishi N, YamamotoM. Isolation and characterization of renal erythropoietin-producingcells from genetically produced anemia mice. PLoS One.2011;6(10):e25839.
34. Vlahakos DV, Marathias KP, Agroyannis B, Madias NE. Posttransplanterythrocytosis. Kidney Int. 2003;63:1187-1194.
35. Yang Q, Jian J, Katz S, Abramson SB, Huang X. 17β-Estradiol inhibitsiron hormone hepcidin through an estrogen responsive elementhalf-site. Endocrinology. 2012;153(7):3170-3178.
36. Ikeda Y, Tajima S, Izawa-Ishizawa Y, et al. Estrogen regulates hepcidinexpression via GPR30-BMP6-dependent signaling in hepatocytes.PLoS One. 2012;7(7):e40465.
37. Hou Y, Zhang S, Wang L, et al. Estrogen regulates iron homeostasisthrough governing hepatic hepcidin expression via an estrogenresponse element. Gene. 2012;511(2):398-403.
38. Guo W, Li M, Bhasin S. Testosterone supplementation improves anemiain aging male mice. J Gerontol A Biol Sci Med Sci. 2013. [Epubahead of print]. PMID: 23974081.
39. Danesh J, Collins R, Peto R, Lowe GD. Haematocrit, viscosity, erythrocytesedimentation rate: meta-analyses of prospective studies ofcoronary heart disease. Eur Heart J. 2000;21(7):515-520.
40. Schuler B, Arras M, Keller S, et al. Optimal hematocrit for maximalexercise performance in acute and chronic erythropoietin-treatedmice. Proc Natl Acad Sci USA. 2010;107:419-423.
41. Gonzales GF, Gasco M, Tapia V, Gonzales-Castaneda C. High serumtestosterone levels are associated with excessive erythrocytosis inchronic mountain sickness in men. Am J Physiol Endocrinol Metab.2009;296(6):E1319-E1325.
42. Murphy WG, Tong E, Murphy C. Why do women have similarerythropoietin levels to men but lower hemoglobin levels? Blood.2010;116:2821-2862.
43. Fehr T, Ammann P, Garzoni D, et al. Interpretation of erythropoietinlevels in patients with various degrees of renal insufficiency and anemia.Kidney Int. 2004;66:1206-1211.
44. van Patot MC, Gassmann M. Hypoxia: adapting to high altitude bymutating EPAS-1, the gene encoding HIF-2α. High Alt Med Biol.2011;12(2):157-167.